However, the remarkable therapeutic response observed in our study with rapamycin treatment may be in part due to the fact that a prolonged rapamycin treatment inhibits mTORC2 in some types of human cancer cells by preventing mTORC2 complex assembly, blocking the phosphorylation of its substrate AKT at Ser473 [51, 60]. The gene discussed is AKT1; the disease is cancer.